At the 78th Scientific Sessions for the American Diabetes Association, in Orlando, Florida, in June 2018, a new continuous glucose monitor (CGM) was reported by Ronnie Aronson, MD, of LMC Diabetes and Endocrinology in Toronto, Canada. The research study involved 36 individuals with type 1 diabetes, including 6 adults and 30 adolescents. This was the first study of any CGM system for a pediatric population for more than a 14-day monitor duration.
- The Senseonics’ Eversense XL CGM showed acceptable accuracy over 6 months of use.
- The CGM is subcutaneously implanted in an office visit, usually into the upper arm. There is a smart transmitter with a gentle adhesive backing, which is changed by the user as needed.
- The patient is alerted to hyperglycemia and hypoglycemia through vibrations from the transmitter or alerts sent to a mobile application, such as a smart phone or watch.
- The CGM was safe over the 180 day study. The research participants responded favorably to the long sensor life, implant design, and the vibratory alerts.
- One drawback to this CGM is that it requires two fingerstick calibrations per day. Competitors – Dexcom G5 CGM and Abbott’s FreeStyle Libre Flash Glucose Monitoring System have recently overcome this problem. Aronson indicated that Senseonics is currently attempting a new version that would not require the fingersticks.
According to Aronson, after 180 days usage, a different site should be used for the next sensor’s insertion, but additional research should be conducted regarding the safety of same-spot insertion.
According to Dr. Wang:
This is another company that is entering the space of continuous glucose monitoring. They are taking a different approach with an implantable sensor. Future development of sensors and mobile computing technologies may fundamentally change how glucose is controlled with a robotic approach. UCI scientists are developing digital technologies to help patients take better care of their diabetes through artificial intelligence.
Read more about the study.